More about SCN2A Encephalopathy
2. A change in the gene can jam the door open, so the cell fires too easily, or stick it shut, so the cell cannot fire well enough. Those 2 faults produce 2 different conditions from the same gene.
Keep reading about SCN2A Encephalopathy
Gain-of-function changes cause early seizures and the brain injury that repeated seizures bring, which is what doctors mean by developmental and epileptic encephalopathy. Loss-of-function changes more often cause autism, intellectual disability and movement problems, with seizures arriving later if at all.
That split matters for treatment, and it is not something a genetic test report states on its own. Anti-seizure medicines that block sodium channels, such as phenytoin, carbamazepine, oxcarbazepine and lamotrigine, are considered contraindicated when the channel is underactive, so the functional effect of the variant shapes which medicines are safe to try. Families often need a neurologist or geneticist familiar with the specific variant to work out which side of the line their child falls on.
Many children with SCN2A encephalopathy need several seizure medicines at once. Feeding tubes, physical, occupational and speech therapy, and careful seizure monitoring are part of daily life for many families, and the risk of sudden unexpected death in epilepsy (SUDEP) is a conversation every care team should have.
What are the symptoms of SCN2A Encephalopathy?
These are common symptoms of SCN2A Encephalopathy, and how strong they are varies from person to person.
- Seizures beginning in the first days or months of life, often of several types and often hard to control
- Developmental delay, or loss of skills a child had already gained
- Autism or autism-like behavior, with or without seizures
- Low muscle tone, feeding difficulty and trouble with balance or coordination
- Abnormal movements such as stiffening, jerking or writhing
- Intellectual disability, from mild to severe
Who gets SCN2A Encephalopathy?
SCN2A changes almost always arise new in the child (de novo) rather than being inherited, so there is usually no family history. The timing of the first seizure is a clue to the type: seizures before 3 months of age usually mean the channel is overactive (gain of function), while seizures after 3 months, or autism without seizures, more often mean it is underactive (loss of function) or has mixed effects.
A milder form, self-limited infantile epilepsy, often runs in families and causes seizures between 3 and 20 months that stop within about a year with normal development. The FamilieSCN2A Foundation estimates that about 75% of cases are still undiagnosed because genetic testing for autism is not routine.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Which new SCN2A Encephalopathy medicines are in trials?
Investigational medicines Trial Friend tracks for SCN2A Encephalopathy, with trial results, safety findings and where each one stands.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for SCN2A Encephalopathy
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted SCN2A Encephalopathy resources
Reputable organizations and medical references for learning more about SCN2A Encephalopathy, including disease registries, foundation resources, and clinical guidelines.
- MedlinePlus Genetics (NIH) - SCN2A gene
- FamilieSCN2A Foundation - The SCN2A spectrum of autism and epilepsy
- Praxis Precision Medicines - FDA Extends Review Period for Relutrigine NDA (June 29, 2026)
- Praxis Precision Medicines - EMBOLD and EMBRAVE data at the American Epilepsy Society meeting (December 8, 2025)
- Praxis Precision Medicines - FDA Breakthrough Therapy Designation for Elsunersen (June 22, 2026)